- Optimized synthesis process of anticancer drug dacarbazine
-
The invention provides an optimized synthesis process of an anticancer drug dacarbazine. The optimized synthesis process of the anticancer drug dacarbazine comprises the following steps: synthesis ofglycine methyl ester, synthesis of N-formylglycine methyl ester, synthesis of alpha-methyl isocyanoacetate, synthesis of alpha-isocyanoacetamide, synthesis of 5-amino-4-imidazolecarboxamide and synthesis of dacarbazine. Synthesis of the glycine methyl ester comprises the following steps: weighing 7.5 g of glycine and adding the glycine into a 500 mL round-bottom flask, taking 200 mL of redistilledmethanol as a solvent and cooling with stirring in an ice bath for 15 min; weighing 22 mL of thionyl chloride by a syringe and slowly dropwise adding the thionyl chloride into the reaction flask to react overnight at room temperature; and removing excess thionyl chloride and methanol by rotary evaporation at the room temperature, dissolving the residues by using as little hot methanol as possible, quickly adding a large amount of cold diethyl ether, and cooling in the reaction bottle in an ice bath. By improving the synthesis process of the anticancer drug dacarbazine, the optimized synthesisprocess of the anticancer drug dacarbazine has the advantages of reasonable synthesis circuit, cheap raw materials, mild reaction conditions and high total yield, thereby effectively solving the problems and defects in the prior art.
- -
-
Paragraph 0034; 0035
(2019/10/17)
-
- Cell
-
PROBLEM TO BE SOLVED: To provide a nonaqueous electrolyte secondary battery excellent in high temperature characteristics. SOLUTION: In the nonaqueous electrolyte secondary battery, since at least one of compounds expressed in a chemical formula 1 is contained in a solvent, decomposition of electrolyte can be prevented under a high temperature environment, and excellent battery characteristics can be obtained while preserving and using under the high temperature environment. In the formula, R1 and R2 express a hydrogen group, a halogen group, a methyl group, an ethyl group or a group whose part of hydrogen is substituted by a halogen group. Either X or Y is sulfur, and the other denotes either sulfur (S) or oxygen (O). COPYRIGHT: (C)2009,JPOandINPIT
- -
-
-
- THERAPEUTIC FOR HEPATIC CANCER
-
A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.
- -
-
-
- Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
-
Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.
- -
-
-
- Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
-
The invention concerns the use of Ro5-4864, and compounds derived therefrom, for preparing medicines for treating tumoral pathologies. The invention also concerns said compounds combined with an apoptosis-inducing agent, as combination products for simultaneous, separate or prolonged use, in cancer therapy.
- -
-
-
- Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
-
A method for the treatment of emesis in a mammal, which method comprises administering to said mammal an emesis inhibiting amount of a compound which depletes serotonin in the brain of mammals; among which are compounds having the formula: STR1 wherein, R is selected from hydrogen, loweralkyl, trifluoromethyl, carboxyl, or loweralkoxycarbonyl; R1 and R2 are hydrogen or loweralkyl; Z is trifluoromethyl or halogen; the optical isomers and pharmaceutically acceptable salts thereof; two of the preferred compounds of the invention are fenfluramine and norfenfluramine.
- -
-
-
